Objective:

To evaluate the association of sodium-glucose cotransporter-2 inhibitors with kidney, cardiovascular, and hepatic outcomes in patients with type 2 diabetes and cirrhosis.

Key Findings:

• SGLT2 inhibitors associated with lower risk of end-stage kidney disease compared to DPP-4 inhibitors.
• Reduced risk of acute kidney injury in patients receiving SGLT2 inhibitors.
• Lower incidence of major adverse cardiovascular events among SGLT2 inhibitor users.
• Fewer hepatic decompensation events observed in patients on SGLT2 inhibitors.

Interpretation:

SGLT2 inhibitors may offer significant cardiorenal and hepatic benefits for patients with type 2 diabetes and cirrhosis, warranting further prospective studies.

Limitations:

• Lack of laboratory data on cirrhosis severity in the administrative database.
• Residual confounding cannot be fully excluded despite statistical adjustments.

Conclusion:

SGLT2 inhibitors demonstrate potential advantages in managing complications associated with type 2 diabetes and cirrhosis, though further research is necessary.